Abo Bibliothek: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 1045-4403

ISSN Online: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention

Volumen 20, Ausgabe 1, 2010, pp. 17-34
DOI: 10.1615/CritRevEukarGeneExpr.v20.i1.20
Get accessGet access

ABSTRAKT

Triple negative breast cancer is a subtype of breast cancer that lacks expression of an estrogen receptor (ER), a progesterone receptor (PR), and HER2. It is characterized by its unique molecular profile, aggressive behavior, and distinct pattern of metastasis. Epidemiological studies show a high prevalence of triple negative breast cancer among younger women and those of African descent. Although sensitive to chemotherapy, early relapse is common, and a predilection for visceral metastasis, including brain metastasis, has been described. Gene-expression profiling approaches demonstrated that triple negative breast cancer is a heterogeneous group of diseases composed of different, molecularly distinct subtypes. Although not synonymous, the majority of triple negative breast cancers carry the "basal-like" molecular profile on gene-expression arrays. However, several studies have shown that triple negative breast cancer includes tumors with a non-basal expression profile and, in particular, the "normal-breast," the "multiple marker negative," and the recently identified "claudin-negative" subtypes. Target-based agents, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly-ADP-ribose polymerase (PARP) inhibitors, are currently in clinical trials and hold promise in the treatment of this aggressive disease.

REFERENZIERT VON
  1. Kim Elizabeth M.H., Mueller Kelly, Gartner Elaina, Boerner Julie, Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells, Journal of Surgical Research, 185, 1, 2013. Crossref

  2. Normanno Nicola, Rachiglio Anna Maria, Roma Cristin, Fenizia Francesca, Esposito Claudia, Pasquale Raffaella, La Porta Maria Libera, Iannaccone Alessia, Micheli Filippo, Santangelo Michele, Bergantino Francesca, Costantini Susan, De Luca Antonella, Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities, Journal of Cellular Biochemistry, 114, 3, 2013. Crossref

  3. Mathe Andrea, Wong-Brown Michelle, Morten Brianna, Forbes John F., Braye Stephen G., Avery-Kiejda Kelly A., Scott Rodney J., Novel genes associated with lymph node metastasis in triple negative breast cancer, Scientific Reports, 5, 1, 2015. Crossref

  4. Mella Mikko, Kauppila Joonas H, Karihtala Peeter, Lehenkari Petri, Jukkola-Vuorinen Arja, Soini Ylermi, Auvinen Päivi, Vaarala Markku H, Ronkainen Hanna, Kauppila Saila, Haapasaari Kirsi-Maria, Vuopala Katri S, Selander Katri S, Tumor infiltrating CD8+T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma, OncoImmunology, 4, 6, 2015. Crossref

  5. Turksen Kursad, Claudins and Cancer Stem Cells, Stem Cell Reviews and Reports, 7, 4, 2011. Crossref

  6. Srinivasaraghavan Vaishnavi, Strobl Jeannine, Agah Masoud, Microelectrode bioimpedance analysis distinguishes basal and claudin-low subtypes of triple negative breast cancer cells, Biomedical Microdevices, 17, 4, 2015. Crossref

  7. Subramaniam Venkateswaran, Ace Olga, Prud'homme Gerald J., Jothy Serge, Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells, Experimental and Molecular Pathology, 90, 1, 2011. Crossref

  8. Cheng Shi-Yann, Yang Yao-Chih, Ting Kuan-lun, Wen Su-Ying, Viswanadha Vijaya Padma, Huang Chih-Yang, Kuo Wei-Wen, Lactate dehydrogenase downregulation mediates the inhibitory effect of diallyl trisulfide on proliferation, metastasis, and invasion in triple-negative breast cancer, Environmental Toxicology, 32, 4, 2017. Crossref

  9. Mathe Andrea, Wong-Brown Michelle, Locke Warwick J., Stirzaker Clare, Braye Stephen G., Forbes John F., Clark Susan J., Avery-Kiejda Kelly A., Scott Rodney J., DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients, Scientific Reports, 6, 1, 2016. Crossref

  10. Chandler Madison R., Keene Kimberly S., Tuomela Johanna M., Forero-Torres Andres, Desmond Renee, Vuopala Katri S., Harris Kevin W., Merner Nancy D., Selander Katri S., Ahmad Aamir, Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans, PLOS ONE, 12, 9, 2017. Crossref

  11. Chen Yu-Hsiang, Hancock Bradley A., Solzak Jeffrey P., Brinza Dumitru, Scafe Charles, Miller Kathy D., Radovich Milan, Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy, npj Breast Cancer, 3, 1, 2017. Crossref

  12. Salek Roham, Varshoee Tabrizi Fatemeh, Ghaffarzadegan Kamran, Sabouri Golnaz, Fanipakdel Azar, A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran, Iranian Journal of Cancer Prevention, In Press, In Press, 2017. Crossref

  13. Conti Laura, Lanzardo Stefania, Arigoni Maddalena, Antonazzo Roberta, Radaelli Enrico, Cantarella Daniela, Calogero Raffaele A., Cavallo Federica, The noninflammatory role of high mobility group box 1/toll‐like receptor 2 axis in the self‐renewal of mammary cancer stem cells, The FASEB Journal, 27, 12, 2013. Crossref

  14. Al-Mahmood Sumayah, Sapiezynski Justin, Garbuzenko Olga B., Minko Tamara, Metastatic and triple-negative breast cancer: challenges and treatment options, Drug Delivery and Translational Research, 8, 5, 2018. Crossref

  15. TUOMELA JOHANNA, SANDHOLM JOUKO, KAUPPILA JOONAS H., LEHENKARI PETRI, HARRIS KEVIN W., SELANDER KATRI S., Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer, Oncology Letters, 6, 6, 2013. Crossref

  16. Avraham Hava Karsenty, Jiang Shuxian, Wang Lili, Fu Yigong, Avraham Shalom, Cellular and Molecular Mechanisms Involved in Breaching of the Blood–Brian Barrier by Circulating Breast Cancer Cells, in Breast Cancer Metastasis and Drug Resistance, 2013. Crossref

  17. 韩 建冬, Application of Biomarkers for Common Cancers in Molecular Diagnosis, Medical Diagnosis, 09, 01, 2019. Crossref

  18. Bermejo Justo L, Huang Guanmengqian, Manoochehri Mehdi, Mesa Karen G, Schick Matthias, Silos Rosa G, Ko Yon-Dschun, Brüning Thomas, Brauch Hiltrud, Lo Wing-Yee, Hoheisel Jörg D, Hamann Ute, Long intergenic noncoding RNA 299 methylation in peripheral blood is a biomarker for triple-negative breast cancer, Epigenomics, 11, 1, 2019. Crossref

Zukünftige Artikel

PRMT6 promotes the immune evasion of gastric cancer via upregulating ANXA1 Liang Xu, Fenger Zhang, Binqi Yu, Shengnan Jia, Sunfu Fan PURPL promotes M2 macrophage polarization in lung cancer via regulating RBM4/xCT signaling Jipeng Guo, Chongwen Gong, Hao Wang SIAH1 promotes the pyroptosis of cardiomyocytes in diabetic cardiomyopathy via regulating IκB-α/NF-κB signaling Jinbin Wu, Yaoming Yan SLC7A2-mediated lysine catabolism inhibits immunosuppression in triple negative breast cancer Yuanyuan Sun, Yaqing Li, Chengying Jiang, Chenying Liu, Yuanming Song SIAH2-mediated degradation of ACSL4 inhibits the anti-tumor activity of CD8+ T cells in hepatocellular carcinoma Fangzheng Shu, Yuhua Shi, Xiangxiang Shan, Wenzhang Zha, Rengen Fan, Wanjiang Xue RBM15-mediated N6-methyl adenosine (m6A) modification of EZH2 drives the epithelial-mesenchymal transition of cervical cancer Ruixue Wang, Wenhua Tan Evidence-Based Storytelling and A Strategic Roadmap to Promote Cancer Prevention Via Adolescent HPV Vaccination in Northern New England Matthew Dugan, Gary Stein, Jan Carney, Sheila Clifford-Bova KDM4A-AS1 promotes cell proliferation, migration and invasion via the miR-4306/STX6 axis in hepatocellular carcinoma Wei Cao, Yuhan Ren, Ying Liu, Guoshu Cao, Zhen Chen, Fan Wang HDAC1-mediated downregulation of NEU1 exacerbates the aggressiveness of cervical cancer Nanzi Xie, Sisi Mei, Changlan Dai, Wei Chen Effect of miR-26b-5p on progression of acute myeloid leukemia by regulating USP48-mediated Wnt/β-catenin pathway Yu Xie, Lin Tan, Kun Wu, Deyun Li, Chengping Li
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain